Medication info
Sardivan Tablet 160 mg (Valsartan)

Sardivan Tablet 160 mg (Valsartan)

Prescription medicationTabletOral
Ingredient · strength
Valsartan›160mg / 1 tablet
Manufacturer / importer
Aju Pharmaceuticals Co., Ltd.
Appearance
Oval film-coated tablet in orange color with a gray tint
Packaging
30 tablets/bottle
Approval status
Active

MFDS item code 201207105 · Approved 2012.10.09

Summary

Main use
Treatment of essential hypertension, reduction of the risk of death after myocardial infarction, and treatment of heart failure
Who takes it
Adults · Children
Adult dose
1. Essential hypertension Take with water during or between meals. If possible, take it at the same time each day (e.g., in the morning). 1) Adults: The recommended dose is 80 mg of valsartan orally once daily, regardless of sex or race. The blood pressure-lowering effect develops gradually within 2 weeks and reaches its maximum after 4 weeks. For patients whose blood pressure is not adequately controlled, the dose may be increased to 160 mg once daily or a diuretic may be given concomitantly. If further blood pressure reduction is needed, the dose may be increased to a maximum of 320 mg once daily. 2) Elderly patients (75 years or older): Initiate treatment with 40 mg of this product once daily. 3) Patients with renal impairment: (1) Creatinine clearance 20 ∼ 50 mL/min: No dosage adjustment is required. (2) Creatinine clearance 10 ∼ 20 mL/min: Initiate treatment with 40 mg of this product once daily. (3) Creatinine clearance below 10 mL/min and patients on dialysis: Do not administer this product. 4) Patients with intravascular volume depletion: In patients with intravascular volume depletion (e.g., patients taking high doses of diuretics whose dose cannot be reduced), initiate treatment with 40 mg of this product once daily. 5) Patients with hepatic impairment: In patients with mild or moderate hepatic impairment, initiate treatment with 40 mg of this product once daily; do not exceed 80 mg per day. Do not administer this product to patients with severe hepatic impairment, cirrhosis, or cholestasis. 2. Heart failure Adults: The recommended starting dose is 40 mg of this product orally twice daily. The dose may be increased to 80 mg or 160 mg per dose. When a diuretic is coadministered, consider reducing the diuretic dose. The maximum daily dose is 320 mg, given in divided doses. Triple combination therapy with this product, an ACE inhibitor, and a beta blocker is not recommended. 3. Reduction of the risk of death after myocardial infarction Adults: Treatment may be initiated within 12 hours after the onset of myocardial infarction. The recommended starting dose is 20 mg of this product twice daily, followed over several weeks by gradual dose increases, as tolerated by the patient, to 40 mg, 80 mg, and 160 mg per dose twice daily. Consider dose reduction if symptoms of hypotension or renal failure occur. This product may also be administered to patients receiving other treatments after myocardial infarction (e.g., thrombolytics, acetylsalicylic acid, beta blockers, and statins). However, concomitant use with an ACE inhibitor is not recommended. 4. Patients with renal impairment: No dosage adjustment is required when creatinine clearance is 10 mL/min or greater. However, because there is no experience with use in patients with creatinine clearance below 10 mL/min or in patients on dialysis, do not administer this product. 5. Patients with hepatic impairment: In patients with mild or moderate hepatic impairment, it is preferable not to exceed 80 mg of this product per day. If administering 80 mg or more per day, consider whether the benefits of treatment outweigh the risks when increasing the dose. Do not administer this product to patients with severe hepatic impairment, cirrhosis, or cholestasis.
Child dose
1. Essential hypertension 6) Pediatric patients: Safety and efficacy have not been established in children and adolescents under 18 years of age. 6. Pediatric patients: Safety and efficacy have not been established in children and adolescents under 18 years of age.

Ingredients

Manufacturer
Aju Pharmaceuticals Co., Ltd.

Efficacy & effects

Treatment of essential hypertension, reduction of the risk of death after myocardial infarction, and treatment of heart failure

  • Essential hypertension
  • heart failure
  • left ventricular dysfunction
  • left ventricular systolic dysfunction
View approved original text

This medication is used to treat essential hypertension. It is also beneficial for patients with heart failure who are intolerant to ACE inhibitors and classified as NYHA class II to IV. It has been shown to reduce the risk of mortality in stable patients with left ventricular dysfunction or systolic dysfunction following a myocardial infarction. Therefore, this medication is used for hypertension management as well as for reducing risks after heart failure and myocardial infarction.

How to take

Adult dose

1. Essential hypertension Take with water during or between meals. If possible, take it at the same time each day (e.g., in the morning). 1) Adults: The recommended dose is 80 mg of valsartan orally once daily, regardless of sex or race. The blood pressure-lowering effect develops gradually within 2 weeks and reaches its maximum after 4 weeks. For patients whose blood pressure is not adequately controlled, the dose may be increased to 160 mg once daily or a diuretic may be given concomitantly. If further blood pressure reduction is needed, the dose may be increased to a maximum of 320 mg once daily. 2) Elderly patients (75 years or older): Initiate treatment with 40 mg of this product once daily. 3) Patients with renal impairment: (1) Creatinine clearance 20 ∼ 50 mL/min: No dosage adjustment is required. (2) Creatinine clearance 10 ∼ 20 mL/min: Initiate treatment with 40 mg of this product once daily. (3) Creatinine clearance below 10 mL/min and patients on dialysis: Do not administer this product. 4) Patients with intravascular volume depletion: In patients with intravascular volume depletion (e.g., patients taking high doses of diuretics whose dose cannot be reduced), initiate treatment with 40 mg of this product once daily. 5) Patients with hepatic impairment: In patients with mild or moderate hepatic impairment, initiate treatment with 40 mg of this product once daily; do not exceed 80 mg per day. Do not administer this product to patients with severe hepatic impairment, cirrhosis, or cholestasis. 2. Heart failure Adults: The recommended starting dose is 40 mg of this product orally twice daily. The dose may be increased to 80 mg or 160 mg per dose. When a diuretic is coadministered, consider reducing the diuretic dose. The maximum daily dose is 320 mg, given in divided doses. Triple combination therapy with this product, an ACE inhibitor, and a beta blocker is not recommended. 3. Reduction of the risk of death after myocardial infarction Adults: Treatment may be initiated within 12 hours after the onset of myocardial infarction. The recommended starting dose is 20 mg of this product twice daily, followed over several weeks by gradual dose increases, as tolerated by the patient, to 40 mg, 80 mg, and 160 mg per dose twice daily. Consider dose reduction if symptoms of hypotension or renal failure occur. This product may also be administered to patients receiving other treatments after myocardial infarction (e.g., thrombolytics, acetylsalicylic acid, beta blockers, and statins). However, concomitant use with an ACE inhibitor is not recommended. 4. Patients with renal impairment: No dosage adjustment is required when creatinine clearance is 10 mL/min or greater. However, because there is no experience with use in patients with creatinine clearance below 10 mL/min or in patients on dialysis, do not administer this product. 5. Patients with hepatic impairment: In patients with mild or moderate hepatic impairment, it is preferable not to exceed 80 mg of this product per day. If administering 80 mg or more per day, consider whether the benefits of treatment outweigh the risks when increasing the dose. Do not administer this product to patients with severe hepatic impairment, cirrhosis, or cholestasis.

Child dose

1. Essential hypertension 6) Pediatric patients: Safety and efficacy have not been established in children and adolescents under 18 years of age. 6. Pediatric patients: Safety and efficacy have not been established in children and adolescents under 18 years of age.

Precautions

This medication can cause serious harm to the fetus if taken during pregnancy, especially in the second and third trimesters; therefore, it should be discontinued immediately upon confirmation of pregnancy. Patients with an allergy to this drug or those with severely impaired liver or kidney function, as well as women who are pregnant or breastfeeding, should not use it. Elderly patients, those with high potassium levels, or patients with impaired liver function, as well as those with heart valve diseases or ischemic heart disease, should use this medication with caution. This medication can significantly lower blood pressure, so patients at risk for hypotension or those already taking diuretics should start with a lower dose and be closely monitored. During treatment, symptoms such as dizziness, fatigue, cough, diarrhea, and headache may occur, and severe cases should be discussed with a healthcare professional. Regular blood tests may be necessary as kidney function or potassium levels can change. When taking other antihypertensives, diuretics, or potassium-sparing agents, interactions may occur, so it's essential to consult with a doctor or pharmacist. Caution is needed when driving or operating machinery due to the possibility of dizziness. In case of overdose, symptoms such as hypotension and consciousness impairment may occur, necessitating immediate emergency treatment. Safety and efficacy have not been established for children and adolescents, so it is advisable not to use this medication in this population. Store it out of reach of children and ensure it is not transferred to another container.

Side effects

  • headache
  • dizziness
  • viral infection
  • upper respiratory tract infection
  • cough
  • diarrhea
  • fatigue
  • rhinitis
  • sinusitis
  • abdominal pain
Show 60 more
  • stomach pain
  • nausea
  • pharyngitis
  • arthralgia
  • hypotension
  • orthostatic dizziness
  • orthostatic hypotension
  • renal impairment
  • hyperkalemia
  • angioedema
  • heart failure
  • angioedema
  • erythema
  • pruritus
  • serum sickness
  • vasculitis
  • syncope
  • nasal bleeding
  • hepatitis
  • arrhythmia
  • intestinal vascular edema
  • interstitial pneumonia
  • hypoglycemia
  • shock
  • loss of consciousness
  • rhabdomyolysis
  • agranulocytosis
  • leukopenia
  • thrombocytopenia
  • vesicular dermatitis
  • decreased hematocrit
  • decreased hemoglobin
  • neutropenia
  • increased serum creatinine
  • increased potassium
  • increased total bilirubin
  • drowsiness
  • atrial fibrillation
  • vomiting
  • constipation
  • thirst
  • loss of appetite
  • malaise
  • indigestion
  • anemia
  • tinnitus
  • hypertonia
  • reduced motor function
  • confusion
  • chest pain
  • rash
  • myalgia
  • edema
  • weakness
  • insomnia
  • decreased libido
  • myalgia due to rhabdomyolysis
  • asthenia
  • increased creatine kinase
  • elevated myoglobin in blood and urine

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a tightly sealed container to protect it from air and moisture, and it should be kept in a cool place below 30 degrees Celsius. Proper storage helps maintain the effectiveness of the medication.

Appearance and packaging

Appearance

Oval film-coated tablet in orange color with a gray tint

Package unit

30 tablets/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.